Mauritius Telecom and Aprecomm Come Together to Bring Innovation to Customer Experience With Network Intelligence
28.2.2023 14:58:00 EET | Business Wire | Press release
Mauritius Telecom, the largest ISP in Mauritius with cellular and high-speed broadband service distribution, today announced its intent to bring Artificial Intelligence based innovative technology to enhance visibility and optimize its residential Wi-Fi connections through a partnership with Aprecomm. This A.I. technology will help Mauritius Telecom to bring proactive Network Intelligence transformation to improve customer experience and to drastically reduce the time for resolution of customer-end issues across their broadband network covering more than 300,000 households.
Speaking on the development, Mr. Kapil Reesaul, CEO, Mauritius Telecom, said, “Mauritius Telecom is the forefront runner in continuous investments in technology to keep innovating and providing the best service to its consumers. The partnership with Aprecomm will help us in our efforts to ensure the best experience across our broadband consumers with faster and proactive resolution of potential issues.”
Pramod Gummaraj, CEO, Aprecomm, said, “We're excited to team up with Mauritius Telecom and implement cutting-edge technology into their network in order to help them cut down on support ticket response times by as much as half and provide a dramatically better experience for their customers. Network Innovation focused on customer experience could be deployed across in the coming months.”
The measurable improvements offered by the integration between Mauritius Telecom and Aprecomm also lead to lower maintenance cost and improved customer satisfaction for one of the country’s fastest growing ISPs.
“With Aprecomm’s vendor agnostic technology, Mauritius Telecom will be able to manage and monitor Network Elements through a unified interface, ensuring assured internet experience to their customers,” said Guharajan Sivakumar, CTO, Aprecomm.
“Network Automation will allow us to bring the best possible experience to our end customers. Measurable customer experience and proactive actions to improve it will be part of this partnership as Aprecomm technology is aligned towards Network Automation,” said Mr. Yagianath Rosunee, CTO of Mauritius Telecom.
About Mauritius Telecom
Mauritius Telecom is the leading provider of an extensive range of ICT services and solutions for both residential customers and businesses in Mauritius, including fixed, mobile, broadband, TV, mobile money and ICT services. Mauritius Telecom has played a pivotal role in the socio-economic development of Mauritius, paving the way for the growth of the ICT industry, which has become a major pillar of the Mauritian economy. Mauritius Telecom has taken bold initiatives to transform the lives of Mauritians, deploying fibre island-wide to provide ultra-high-speed broadband to all, disrupting the payment landscape with a mobile wallet thus revolutionizing payments in Mauritius, launching in 2021 the first 5G Experience Zones and the first 1Gbps fibre internet to home offer in Mauritius. In 2022 Mauritius Telecom’s mobile service, my.t mobile reached the milestone of one million customers.
- Headquarters: Port Louis, Mauritius
- Website: https://www.telecom.mu, https://www.myt.mu/
- LinkedIn: https://www.linkedin.com/company/mauritius-telecom/
- Facebook: https://www.facebook.com/mauritiustelecom
About Aprecomm
Aprecomm is an industry game-changer with a Network Intelligence Software Stack to understand Customer Experience. Aprecomm offers cloud-based automated solutions to enhance Wired and Wi-Fi network performance. Aprecomm’s patented technology helps in automatically and proactively troubleshooting Wi-Fi issues. This way ISPs and Enterprises will be able to fix them immediately and dramatically minimize down-time. Aprecomm’s solutions help enterprises, ISPs, TSPs improve their business standards through higher reliability, reduced expenses, and speedy ROI.
- Headquarters: Bangalore, India
- Website: https://aprecomm.ai
- LinkedIn: https://in.linkedin.com/company/aprecomm
- Facebook: https://www.facebook.com/aprecomm/
- Twitter: https://twitter.com/aprecomm_ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005801/en/
Contact information
For further details please contact:
Aprecomm
Shankar Peerthy
Email: Peerthy@aprecomm.ai
Contact: +41-78 685 82 58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
